BR9908165A - Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster. - Google Patents

Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster.

Info

Publication number
BR9908165A
BR9908165A BR9908165-2A BR9908165A BR9908165A BR 9908165 A BR9908165 A BR 9908165A BR 9908165 A BR9908165 A BR 9908165A BR 9908165 A BR9908165 A BR 9908165A
Authority
BR
Brazil
Prior art keywords
role
indole
ester
salt
propionic acid
Prior art date
Application number
BR9908165-2A
Other languages
English (en)
Inventor
A Pappolla Miguel
Original Assignee
Univ South Alabama
Univ New York
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ South Alabama, Univ New York filed Critical Univ South Alabama
Publication of BR9908165A publication Critical patent/BR9908165A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

''PROCESSOS DE PREVENçãO DE UM EFEITO CITOTóXICO DE PROTEìNA BETA AMILóIDE EM CéLULAS, DE TRATAMENTO DE UMA DOENçA FIBRILOGêNICA EM UM SUJEITO HUMANO, DE DIMINUIçãO DA OXIDAçãO EM UMA AMOSTRA BIOLóGICA E DE TRATAMENTO DE DOENçAS OU OUTROS QUADROS EM QUE RADICAIS LIVRES E/OU TENSãO OXIDATIVA DESEMPENHAM UM PAPEL, E, USO DE áCIDO INDOL-3-PROPIÈNICO OU UM SEU SAL OU éSTER'' Os efeitos citotóxicos da proteína beta amilóide em células são prevenidos contactando-se as células com uma quantidade efetiva de um ácido indol-3-propiónico ou seu sal ou éster. Além disso, uma doença fibrilogênica pode ser tratada em um sujeito humano administrando-se ao sujeito humano uma quantidade de um ácido indol-3-propiónico ou um seu sal ou éster que é efetiva para impedir ou reverter a fibrilogênese. A oxidação em uma amostra biológica pode ser diminuída contactando-se a amostra biológica com uma quantidade efetiva de um ácido indol-3-propiónico ou um seu sal ou éster. Adicionalmente, doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel podem ser tratadas administrando-se uma quantidade efetiva de um ácido indol-3-propiónico ou um seu sal ou éster.
BR9908165-2A 1998-02-23 1999-02-23 Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster. BR9908165A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7555598P 1998-02-23 1998-02-23
US11256598P 1998-12-16 1998-12-16
PCT/US1999/003906 WO1999042102A1 (en) 1998-02-23 1999-02-23 Indole-3-propionic acids, salts and esters thereof used as medicaments

Publications (1)

Publication Number Publication Date
BR9908165A true BR9908165A (pt) 2000-10-31

Family

ID=26757006

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9908165-2A BR9908165A (pt) 1998-02-23 1999-02-23 Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster.

Country Status (18)

Country Link
US (1) US6395768B1 (pt)
EP (1) EP1056452B1 (pt)
JP (2) JP5627160B2 (pt)
CN (1) CN1147299C (pt)
AT (1) ATE333275T1 (pt)
AU (1) AU757925B2 (pt)
BR (1) BR9908165A (pt)
CA (1) CA2321455C (pt)
DE (1) DE69932414T2 (pt)
DK (1) DK1056452T3 (pt)
EA (1) EA005244B1 (pt)
ES (1) ES2270585T3 (pt)
HK (1) HK1036588A1 (pt)
IL (2) IL137848A0 (pt)
MX (1) MXPA00008216A (pt)
NZ (1) NZ506260A (pt)
PT (1) PT1056452E (pt)
WO (1) WO1999042102A1 (pt)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6720355B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Sodium dodecyl sulfate compositions for inactivating prions
US6719988B2 (en) 1997-02-21 2004-04-13 The Regents Of The University Of California Antiseptic compositions for inactivating prions
US6322802B1 (en) 1999-06-01 2001-11-27 The Regents Of The University Of California Method of sterilizing
US6419916B1 (en) 1999-06-01 2002-07-16 The Regents Of The University Of California Assay for compounds which affect conformationally altered proteins
DE10006139A1 (de) * 2000-02-11 2001-08-16 Merck Patent Gmbh Indol-3-yl-Derivate
US7491699B2 (en) 2002-12-09 2009-02-17 Ramot At Tel Aviv University Ltd. Peptide nanostructures and methods of generating and using the same
ATE426575T1 (de) 2003-01-07 2009-04-15 Univ Ramot Peptidenanostrukturen die fremdmaterial enthalten,und verfahren zur herstellung derselben
US7348338B2 (en) * 2003-07-17 2008-03-25 Plexxikon, Inc. PPAR active compounds
BRPI0412684A (pt) * 2003-07-17 2006-10-03 Plexxinko Inc compostos ppar-ativos
US7125861B2 (en) * 2003-07-31 2006-10-24 Rolland F Hebert Water-soluble chitosan-indole-3-propionic acid conjugates
JP4917889B2 (ja) 2003-09-25 2012-04-18 テル アヴィヴ ユニヴァーシティ フューチャー テクノロジー ディヴェロップメント エル．ピー． アミロイド関連疾患を処置するための組成物及びその使用方法
US20070105937A1 (en) * 2003-12-22 2007-05-10 Miguel Pappolla Indole-3-propionamide and derivatives thereof
EP1781310B1 (en) 2004-08-02 2015-10-14 Ramot at Tel Aviv University Ltd. Articles of peptide nanostructures and method of forming the same
US7732479B2 (en) 2004-08-19 2010-06-08 Tel Aviv University Future Technology Development L.P. Compositions for treating amyloid associated diseases
AU2005311826A1 (en) * 2004-11-30 2006-06-08 Plexxikon, Inc. Indole derivatives for use as PPAR active compounds
EP1819673A2 (en) * 2004-11-30 2007-08-22 Plexxikon, Inc. Indole derivatives for use as ppar active compounds
JP2008545663A (ja) * 2005-05-27 2008-12-18 クイーンズ ユニバーシティ アット キングストン タンパク質フォールディング障害の治療
CA2621275A1 (en) * 2005-09-07 2007-03-15 Plexxikon, Inc. 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds
RU2008108221A (ru) * 2005-09-07 2009-10-20 Плекссикон, Инк. (Us) Соединения, активные в отношении ppar (рецепторов активаторов пролиферации пероксисом)
EP1973928A2 (en) 2005-10-11 2008-10-01 Ramot at Tel-Aviv University Ltd. Self-assembled fmoc-ff hydrogels
US20080207731A1 (en) * 2006-08-23 2008-08-28 Intellect Neurosciences, Inc. 3-(3-indolyl) propionic acid calcium salt and method of making 3-(3-indolyl) propionic acid free acid therefrom
PE20090159A1 (es) * 2007-03-08 2009-02-21 Plexxikon Inc COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs
US9744155B2 (en) * 2012-03-28 2017-08-29 Ixcela, Inc. IPA as a therapeutic agent, as a protective agent, and as a biomarker of disease risk
CN105934520A (zh) * 2014-01-31 2016-09-07 伊克斯塞拉有限公司 作为生物标志物的共价键代谢物
CN108125950B (zh) * 2017-12-28 2020-09-25 崔明 吲哚丙酸在制备用于预防和/或治疗肿瘤放疗副反应的药物中的用途
JP2020083827A (ja) * 2018-11-27 2020-06-04 国立研究開発法人農業・食品産業技術総合研究機構 ケミカルシャペロンまたは神経細胞死の抑制剤
US11041847B1 (en) 2019-01-25 2021-06-22 Ixcela, Inc. Detection and modification of gut microbial population
CN109674787A (zh) * 2019-02-01 2019-04-26 百迈康生物医药科技(广州)有限公司 一种防治缺血性心脏病的药物及其应用
CN109730993A (zh) * 2019-02-28 2019-05-10 北京大学人民医院(北京大学第二临床医学院) 吲哚丙酸在制备防治类风湿关节炎药物中的应用
WO2020185913A1 (en) * 2019-03-12 2020-09-17 Intellect Neurosciences, Inc. Indole-3-propionic acids and salts and esters thereof for treating skin disorders
EP4076424A1 (en) * 2019-12-20 2022-10-26 Basf Se Composition for the treatment of amyloid-beta associated diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4536505A (en) * 1983-05-17 1985-08-20 Ciba-Geigy Corporation Certain N-(pyridyl) indoles
JP2602735B2 (ja) * 1989-09-27 1997-04-23 株式会社大塚製薬工場 抗活性酸素剤
JPH0578247A (ja) * 1991-03-04 1993-03-30 Mitsubishi Gas Chem Co Inc 活性酸素消去剤
JPH0578248A (ja) * 1991-03-04 1993-03-30 Mitsubishi Gas Chem Co Inc 活性酸素消去剤
AU3067592A (en) * 1991-11-18 1993-06-15 G.D. Searle & Co. Derivatives of cyclic phenolic thioethers as inhibitors or stimulators of superoxide generation
AU672224B2 (en) * 1992-08-06 1996-09-26 Warner-Lambert Company 2-thioindoles (selenoindoles) and related disulfides (selenides) which inhibit protein tyrosine kinases and whichhave antitumor properties
IT1265101B1 (it) * 1993-07-23 1996-10-30 Erba Carlo Spa Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico
JPH0881442A (ja) * 1994-07-14 1996-03-26 Otsuka Pharmaceut Co Ltd 環状アミド誘導体
EP0804416A1 (en) * 1994-07-27 1997-11-05 Sankyo Company Limited Heterocyclic compounds, useful as allosteric effectors at muscarinic receptors
JPH08175993A (ja) * 1994-12-21 1996-07-09 Green Cross Corp:The 抗酸化剤
JPH09249567A (ja) * 1996-01-12 1997-09-22 Otsuka Pharmaceut Co Ltd 医薬組成物
TW430660B (en) * 1996-05-30 2001-04-21 Mochida Pharm Co Ltd Novel benzindole derivatives for neuron cell protection, processes for production, and the pharmaceutical compounds containing them

Also Published As

Publication number Publication date
EP1056452B1 (en) 2006-07-19
DE69932414D1 (de) 2006-08-31
WO1999042102A8 (en) 2001-02-15
CN1147299C (zh) 2004-04-28
ATE333275T1 (de) 2006-08-15
PT1056452E (pt) 2006-12-29
ES2270585T3 (es) 2007-04-01
IL137848A0 (en) 2001-10-31
CA2321455C (en) 2010-10-19
EP1056452A1 (en) 2000-12-06
IL137848A (en) 2010-11-30
JP5627160B2 (ja) 2014-11-19
AU757925B2 (en) 2003-03-13
JP2012017343A (ja) 2012-01-26
EA200000874A1 (ru) 2001-02-26
CN1292693A (zh) 2001-04-25
MXPA00008216A (es) 2004-11-22
WO1999042102A1 (en) 1999-08-26
JP2002503691A (ja) 2002-02-05
CA2321455A1 (en) 1999-08-26
US6395768B1 (en) 2002-05-28
HK1036588A1 (en) 2002-01-11
DE69932414T2 (de) 2007-02-22
DK1056452T3 (da) 2006-11-20
NZ506260A (en) 2003-05-30
AU2782899A (en) 1999-09-06
EA005244B1 (ru) 2004-12-30

Similar Documents

Publication Publication Date Title
BR9908165A (pt) Processos de prevenção de um citotóxico de proteìna beta amilóide em células, de tratamento de uma fibrilogênica em um sujeito humano, de diminuição da oxidação em uma amostra biológica e de tratamento de doenças ou outros quadros em que radicais livres e/ou tensão oxidativa desempenham um papel, e, uso de ácido indol-3-propiÈnico ou um seu sal ou éster.
DE3586859D1 (de) Mittel zur behandlung und zum schutz der haut.
DE69636514D1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
ATE209908T1 (de) RADIKALFÄNGER (ßSPIN TRAPSß) ZUR BEHANDLUNG VON MIT OXIDATION VON LIPIDEN UND PROTEINEN VERBUNDENEN ERKRANKUNGEN
DE69010162D1 (de) Zusammensetzung zur Behandlung von Entzündung.
MX9307886A (es) Composicion farmaceutica y proceso para su preparacion.
Maciel et al. Acute treatment with ketamine and chronic treatment with minocycline exert antidepressant-like effects and antioxidant properties in rats subjected different stressful events
ATE91628T1 (de) Sauerwiderstehender fibroblast-wachstumsfaktor, zubereitung zur behandlung von magen-darmweggeschw¨rkrankheiten.
ES2033667T3 (es) Composicion farmaceutica que contiene fracciones de extractos de timo.
Farahpour et al. Effect of in situ delivery of acetyl-L-carnitine on peripheral nerve regeneration and functional recovery in transected sciatic nerve in rat
BR9805318A (pt) Método para tratamento de infecções dos olhos com azitromicina.
Bitencourt et al. Safety and patient subjective efficacy of using galvanopuncture for the treatment of striae distensae
DE3781686D1 (de) Fettsaeure und cyclosporin enthaltende zusammensetzung mit ermaessigter nephrotoxizitaet.
ATE90563T1 (de) Arzneimittelzubereitung aus esterderivaten des hecogenins und dessen verwendung zur behandlung von benigner prostatahyperplasie.
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
ATE173297T1 (de) Verfahren zur erkennung und behandlung anomaler zellen
ES2044170T3 (es) Sal de estroncio, su procedimiento de preparacion y las composiciones farmaceuticas que la contienen.
TR200100897T2 (tr) Lipid metabolizma bozukluklarının tedavisinde safra asitleriyle bağlı propanolamin türevleri.
NO890801L (no) Fremgangsmaate for fremstilling av lysyloxydaseinhibitorer.
DE3850728T2 (de) Methode zur Bestimmung des Verhaltens von Medikamenten in Lebewesen.
US4507277A (en) Composition and method for stimulating the synthesis of the melanotic pigment of the skin
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
Sajjad et al. The The Therapeutic Effects of Autologous Platelet-Rich Plasma Gel on Cutaneous Wound Healing in Rescued Horses: The Effects of Autologous Platelet-Rich Plasma Gel on skin Wound Healing in Horses
Spadoni et al. Effect of the administration of xanthine on the appearance of xanthine oxidase activity in the liver of growing rats
DE69430807T2 (de) Verfahren zur behandlung von lebererkrankungen und ähnlichen indikationen mit vasodilatierenden wirkstoffen

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRESENTE PEDIDO, UMA VEZ QUE ESTE INCIDE NO ARTIGO 10 ( VIII ) DA LPI ( LEI 9279/96 )

B12B Appeal against refusal [chapter 12.2 patent gazette]